Page 502 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 502

488     SECTION V  Drugs That Act in the Central Nervous System


                                                                                                          2+
                                                                                               2+
                 from its stores in the sarcoplasmic reticulum (see Figures 13–1   have a hereditary alteration in Ca -induced Ca  release via the
                 and 27–10).  This activator calcium brings about the tension-  RyR1 channel or impairment in the ability of the sarcoplasmic
                                                                                                      2+
                 generating interaction of actin with myosin. Calcium is released   reticulum to sequester calcium via the Ca  transporter (Figure
                 from the sarcoplasmic reticulum via a calcium channel, called the   27–10). Several mutations associated with this risk have been
                 ryanodine receptor (RyR) channel because the plant alkaloid   identified. After administration of one of the triggering agents,
                 ryanodine combines with a receptor on the channel protein. In   there is a sudden and prolonged release of calcium, with massive
                 the case of the skeletal muscle RyR1 channel, ryanodine facilitates   muscle  contraction,  lactic  acid  production,  and  increased  body
                 the open configuration.                             temperature.  Prompt  treatment  is  essential  to  control  acidosis
                                                                     and body temperature and to reduce calcium release. The latter
                            O                                        is accomplished by administering intravenous dantrolene, starting
                                                                     with a dose of 1 mg/kg IV, and repeating as necessary to a maxi-
                        HN     N  N  CH                  NO 2
                                                                     mum dose of 10 mg/kg.
                                            O
                       O             Dantrolene
                                                                     ANTISPASMODICS: DRUGS USED TO
                   Dantrolene interferes with the release of activator calcium   TREAT ACUTE LOCAL MUSCLE SPASM
                 through this sarcoplasmic reticulum calcium channel by binding
                 to the RyR1 and blocking the opening of the channel. Motor units   A large number of less well-studied, centrally active drugs
                 that contract rapidly are more sensitive to the drug’s effects than   (eg,  carisoprodol, chlorphenesin, chlorzoxazone, cycloben-
                 are slower-responding units. Cardiac muscle and smooth muscle   zaprine, metaxalone, methocarbamol, and orphenadrine) are
                 are minimally depressed because the release of calcium from their   promoted for the relief of acute muscle spasm caused by local
                 sarcoplasmic reticulum involves a different RyR channel (RyR2).  tissue trauma or muscle strains. It has been suggested that these
                   Treatment  with  dantrolene  is  usually  initiated  with  25  mg   drugs act primarily at the level of the brainstem. Cyclobenzap-
                 daily as a single dose, increasing to a maximum of 100 mg four   rine may be regarded as the prototype of the group. Cycloben-
                 times daily as tolerated. Only about one third of an oral dose of   zaprine is structurally related to the tricyclic antidepressants and
                 dantrolene is absorbed, and the elimination half-life of the drug   produces antimuscarinic side effects. It is ineffective in treating
                 is approximately 8 hours. Major adverse effects are generalized   muscle spasm due to cerebral palsy or spinal cord injury. As a
                 muscle weakness, sedation, and occasionally hepatitis.  result of its strong antimuscarinic actions, cyclobenzaprine may
                   A special application of dantrolene is in the treatment of   cause  significant  sedation,  as well  as  confusion  and transient
                 malignant hyperthermia, a rare heritable disorder that can be   visual hallucinations. The dosage of cyclobenzaprine for acute
                 triggered by a variety of stimuli, including general anesthetics (eg,   injury-related muscle spasm is 20–40 mg/d orally in divided
                 volatile anesthetics) and neuromuscular blocking drugs (eg, succi-  doses. This drug class carries risks of significant adverse events
                 nylcholine; see also Chapter 16). Patients at risk for this condition   and abuse potential.





                  SUMMARY Skeletal Muscle Relaxants

                  Subclass,    Mechanism                                                       Pharmacokinetics,
                  Drug         of Action          Effects               Clinical Applications  Toxicities, Interactions
                  DEPOLARIZING NEUROMUSCULAR BLOCKING AGENT
                  •  Succinylcholine  Agonist at nicotinic   Initial depolarization causes   Placement of endotracheal tube   Rapid metabolism by plasma
                               acetylcholine (ACh)   transient contractions, followed   at start of anesthetic procedure    cholinesterase • normal duration
                               receptors, especially at   by prolonged flaccid paralysis    • rarely, control of muscle   ~5 min • Toxicities: Arrhythmias
                               neuromuscular junctions    • depolarization is then followed   contractions in status epilepticus  • hyperkalemia • transient increased
                               • depolarizes • may   by repolarization that is also            intra-abdominal, intraocular
                               stimulate ganglionic   accompanied by paralysis                 pressure • postoperative muscle
                               nicotinic ACh and cardiac                                       pain
                               muscarinic ACh receptors
                                                                                                                (continued)
   497   498   499   500   501   502   503   504   505   506   507